Quercetin in cancer treatment, alone or in combination with conventional therapeutics?

Current Medicinal Chemistry

Volumn 22, Issue 26, 2015, Pages 3025-3039

  Brito, Ana Filipa ^a,b   Ribeiro, Marina ^a,c   Abrantes, Ana Margarida ^a,b   Pires, Ana Salomé ^a,b,c   Teixo, Ricardo Jorge ^a   Tralhão, José Guilherme ^a,d   Botelho, Maria Filomena ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Cancer; Flavonoids; Flavonols; Quercetin; Synergism; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLAVONOID; FLUOROURACIL; GEMCITABINE; GLUCOSE TRANSPORTER 1; LAPATINIB; NATURAL PRODUCT; OXALIPLATIN; QUERCETIN; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; TRICHOSTATIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CELL PROTECTION; CHEMOSENSITIZATION; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; RADIATION PROTECTION; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, MULTIPLE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; QUERCETIN;

EID: 84942155857     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150812145435     Document Type: Article

References (105)

1. Nomura, M.; Takahashi, T.; Nagata, N.; Tsutsumi, K.; Kobayashi, S.; Akiba, T.; Yokogawa, K.; Moritani, S.; Miyamoto, K. Inhibitory mechanisms of flavonoids on insulinstimulated glucose uptake in MC3T3-G2/PA6 adipose cells. Biol. Pharm. Bull., 2008, 31, 1403-1409.
2. Park, J. B. Flavonoids are potential inhibitors of glucose uptake in U937 cells. Biochem. Biophys. Res. Commun., 1999, 260, 568-574.
3. Kanadaswami, C.; Lee, L.; Lee, P. H.; Hwang, J. J.; Ke, F. C.; Huang, Y. T.; Lee, M. T. The antitumor activities of flavonoids. In Vivo (Brooklyn), 2005, 19, 895-910.
4. Seufi, A. M.; Ibrahim, S. S.; Elmaghraby, T. K.; Hafez, E. E. Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences. J. Exp. Clin. Cancer Res., 2009, 28, 80-88.
5. Adebamowo, C. A.; Cho, E.; Sampson, L.; Katan, M. B.; Spiegelman, D.; Willett, W. C.; Holmes, M. D. Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. Int. J. Cancer, 2005, 114, 628-633.
6. Tapas, A. R.; Sakarkar, D. M.; Kakde, R. B. Flavonoids as nutraceuticals: A review. Trop. J. Pharm. Res., 2008, 7, 1089-1099.
7. Kite, G. C.; Porter, E. A.; Denison, F. C.; Grayer, R. J.; Veitch, N. C.; Butler, I.; Simmonds, M. S. J. Data-directed scan sequence for the general assignment of Cglycosylflavone O-glycosides in plant extracts by liquid chromatography-ion trap mass spectrometry. J. Chromatogr. A, 2006, 1104, 123-131.
8. Kite, G. C.; Veitch, N. C. Identification of common glycosyl groups of flavonoid O-glycosides by serial mass spectrometry of sodiated species. Rapid Commun. Mass Spectrom., 2011, 25, 2579-2590.
9. Martin, H-J.; Kornmann, F.; Fuhrmann, G. F. The inhibitory effects of flavonoids and antiestrogens on the Glut1 glucose transporter in human erythrocytes. Chem. Biol. Interact., 2003, 146, 225-235.
10. Strobel, P.; Allard, C.; Perez-Acle, T.; Calderon, R.; Aldunate, R.; Leighton, F. Myricetin, quercetin and catechingallate inhibit glucose uptake in isolated rat adipocytes. Biochem. J., 2005, 386, 471-478.
11. Amann, T.; Hellerbrand, C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert. Opin. Ther. Targets, 2009, 13, 1411-1427.
12. Pérez, A.; Ojeda, P.; Ojeda, L.; Salas, M.; Rivas, C. I.; Vera, J. C.; Reyes, A. M. Hexose transporter GLUT1 harbors several distinct regulatory binding sites for flavones and tyrphostins. Biochemistry, 2011, 50, 8834-8845.
13. Vargas, A. J.; Sittadjody, S.; Thangasamy, T.; Mendonza, E. E.; Limesand, K. H.; Burd, R. Exploiting tyrosinase expression and activity in melanocytic tumors: quercetin and the central role of p53. Integr. Cancer Ther., 2011, 10, 328- 340.
14. Vera, J. C.; Reyes, A. M.; Velásquez, F. V.; Rivas, C. I.; Zhang, R. H.; Strobel, P.; Slebe, J. C.; Nuñez-Alarcón, J.; Golde, D. W. Direct inhibition of the hexose transporter GLUT1 by tyrosine kinase inhibitors. Biochemistry, 2001, 40, 777-790.
15. Gilbert, E. R.; Liu, D. Anti-diabetic functions of soy isoflavone genistein: mechanisms underlying its effects on pancreatic β-cell function. Food. Funct., 2013, 4, 200-212.
16. Crespy, V.; Williamson, G. A review of the health effects of green tea catechins in in vivo animal models. J. Nutr., 2004, 134, 3431S-3440S.
17. Williamson, G. Possible effects of dietary polyphenols on sugar absorption and digestion. Mol. Nutr. Food Res., 2013, 57, 48-57.
18. Wein, S.; Schrader, E.; Rimbach, G.; Wolffram, S. Oral green tea catechins transiently lower plasma glucose concentrations in female db/db mice. J. Med. Food, 2013, 16, 312-317.
19. Pereira, D. F.; Cazarolli, L. H.; Lavado, C.; Mengatto, V.; Figueiredo, M. S. R. B.; Guedes, A.; Pizzolatti, M. G.; Silva, F. R. M. B. Effects of flavonoids on α-glucosidase activity: potential targets for glucose homeostasis. Nutrition, 2011, 27, 1161-1167.
20. Babu, P. V. A.; Liu, D.; Gilbert, E. R. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J. Nutr. Biochem., 2013, 24, 1777-1789.
21. Mohan, S.; Nandhakumar, L. Role of various flavonoids: Hypotheses on novel approach to treat diabetes. J. Med. Hypotheses Ideas, 2014, 8, 1-6.
22. Kim, J. H.; Kang, M. J.; Choi, H. N.; Jeong, S. M.; Kim, J. I. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr. Res. Pract., 2011, 5, 107-111.
23. Chen, C.; Zhou, J.; Ji, C. Quercetin: A potential drug to reverse multidrug resistance. Life Sci., 2010, 87, 333-338.
24. Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S.; Itoh, N.; Shibuya, M.; Fukami, Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 1987, 262, 5592-5595.
25. Ferraresi, R.; Troiano, L.; Roat, E.; Lugli, E.; Nemes, E.; Nasi, M.; Pinti, M.; Fernandez, M. I. G.; Cooper, E. L.; Cossarizza, A. Essential requirement of reduced glutathione (GSH) for the anti-oxidant effect of the flavonoid quercetin. Free Radic. Res., 2005, 39, 1249-1258.
26. Russo, M.; Spagnuolo, C.; Tedesco, I.; Bilotto, S.; Russo, G. L. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem. Pharmacol., 2012, 83, 6-15.
27. Materska, M. Quercetin and its derivatives: chemical structure and bioactivity - A review. Polish J. Food Nutr. Sci., 2008, 58, 407-413.
28. Moon, Y. J.; Wang, L.; Dicenzo, R.; Morris, M. E. Quercetin pharmacokinetics in humans. Biopharm. Drug Dispos., 2008, 217, 205-217.
29. Graefe, E. U.; Wittig, J.; Mueller, S.; Riethling, A. K.; Drewelow, B.; Pforte, H.; Jacobasch, G.; Derendorf, H.; Veit, M. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol., 2001, 41, 492- 499.
30. Liu, L.; Tang, Y.; Gao, C.; Li, Y.; Chen, S.; Xiong, T.; Li, J.; Du, M.; Gong, Z.; Chen, H.; Liu, L.; Yao, P. Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf. B Biointerfaces, 2014, 115, 125-131.
31. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol., 2007, 35, 495-516.
32. Jeong, J. H.; An, J. Y.; Kwon, Y. T.; Rhee, J. G.; Lee, Y. J. Effects of low dose quercetin: Cancer cell-specific inhition of cell cycle progression. Mol. Biol., 2009, 50, 1820-1827.
33. Priyadarsini, R. V.; Murugan, R. S.; Maitreyi, S.; Ramalingam, K.; Karunagaran, D.; Nagini, S. The flavonoid quercetin induces cell cycle arrest and mitochondriamediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition. Eur. J. Pharmacol., 2010, 649, 84-91.
34. van Zanden, J. J.; van der Woude, H.; Vaessen, J.; Usta, M.; Wortelboer, H. M.; Cnubben, N. H. P.; Rietjens, I. M. C. M. The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem. Pharmacol., 2007, 74, 345-351.
35. Lamson, D. W.; Brignall, M. S. Antioxidants and cancer III: quercetin antioxidants & cancer: quercetin. Altern. Med. Rev., 2000, 5, 196-208.
36. Kim, Y.; Lee, D.; Jeong, J.; Guo, Z.; Lee, Y. Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem. Pharmacol., 2009, 75, 1946-1958.
37. Nöthlings, U.; Murphy, S. P.; Wilkens, L. R.; Henderson, B. E.; Kolonel, L. N. Flavonols and pancreatic cancer risk: The multiethnic cohort study. Am. J. Epidemiol., 2007, 166, 924-931.
38. Lee, L-T.; Huang, Y-T.; Hwang, J-J.; Lee, A. Y-L.; Ke, FC.; Huang, C-J.; Kandaswami, C.; Lee, P-P. H.; Lee, M-T. Transinactivation of the epidermal growth factor receptor tyrosine kinase and focal adhesion kinase phosphorylation by dietary flavonoids: effect on invasive potential of humancarcinoma cells. Biochem. Pharmacol., 2004, 67, 2103- 2114.
39. Williams, R. J.; Spencer, J. P. E.; Rice-Evans, C. Flavonoids: Antioxidants or signaling molecules? Free Radic. Biol. Med., 2004, 36, 838-849.
40. al-Obeidi, F. A.; Wu, J. J.; Lam, K. S. Protein tyrosine kinases: structure, substrate specificity, and drug discovery. Biopolymers, 1998, 47, 197-223.
41. Huang, Y.; Lee, L.; Lee, P. P. H.; Lin, Y. S.; Lee, M. T. Targeting of focal adhesion kinase by flavonoids and smallinterfering RNAs reduces tumor cell migration ability. Anticancer Res., 2005, 2026, 2017-2025.
42. Huang, Y. T.; Hwang, J. J.; Lee, P. P.; Ke, F. C.; Huang, J. H.; Huang, C. J.; Kandaswami, C.; Middleton, E.; Lee, M. T. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br. J. Pharmacol., 1999, 128, 999-1010.
43. Firdous, A. B.; Sharmila, G.; Balakrishnan, S.; Singh, P. R.; Suganya, S.; Srinivasan, N.; Arunakaran, J. Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent against prostate cancer in an in vivo model by inhibiting the EGFR signaling pathway. Food Funct., 2014, 5, 2632-2645.
44. Maso, V.; Calgarotto, A. K.; Franchi, G. C.; Nowill, A. E.; Filho, P. L.; Vassallo, J.; Saad, S. T. O. Multitarget effects of quercetin in leukemia. Cancer Prev. Res. (Phila), 2014, 7, 1240-1250.
45. Volate, S. R.; Davenport, D. M.; Muga, S. J.; Wargovich, M. J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis, 2005, 26, 1450-1456.
46. Yi, L.; Zongyuan, Y.; Cheng, G.; Lingyun, Z.; Guilian, Y.; Wei, G. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci., 2014, 105, 520-527.
47. Gao, X.; Wang, B.; Wei, X.; Men, K.; Zheng, F.; Zhou, Y.; Zheng, Y.; Gou, M.; Huang, M.; Gui, G.; Huang, N.; Qian, Z.; Wei, Y. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale, 2012, 4, 7021-7030.
48. Zhang, J.; Yi, T.; Liu, J.; Zhao, Z. Z.; Chen, H. B. Quercetin induces apoptosis via the mitochondrial pathway in KB and KBv200 cells. J. Agric. Food. Chem., 2013, 61, 2188-2195.
49. Lee, D-H.; Szczepanski, M.; Lee, Y. J. Role of BAX in quercetin-induced apoptosis in human prostate cancer cells. Biochem. Pharmacol., 2012, 75, 2345-2355.
50. Russo, M.; Spagnuolo, C.; Volpe, S.; Tedesco, I.; Bilotto, S.; Russo, G. L. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochem. Pharmacol., 2013, 85, 927-936.
51. Wei, Y. Q.; Zhao, X.; Kariya, Y.; Teshihawara, K.; Ushida, A. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res., 1994, 54, 4952-4957.
52. Aalinkeel, R.; Bindukumar, B.; Reynolds, J. L.; Sykes, D. E.; Mahajan, S. D.; Chadha, K. C.; Schwartz, S. A. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate, 2008, 68, 1773-1789.
53. Angst, E.; Park, J. L.; Moro, A.; Lu, Q. Y.; Lu, X.; Li, G.; King, J.; Chen, M.; Reber, H. A.; Go, V. L.; Eibl, G.; Hines, O.J. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas, 2014, 42, 223-229.
54. Bishayee, K.; Ghosh, S.; Mukherjee, A.; Sadhukhan, R.; Mondal, J.; Khuda-Bukhsh, A.R .Quercetin induces cytochrome- c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: signal cascade and drug-DNA interaction. Cell. Prolif., 2013, 46, 153-163.
55. Wang, Y. H.; Chao, P. D.; Hsiu, S. L.; Wen, K. C.; Hou, Y. C. Lethal quercetin-digoxin interaction in pigs. Life Sci., 2004, 74, 1191-1197.
56. Shin, S-C.; Choi, J-S.; Li, X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm., 2006, 313, 144-149.
57. Kim, K-A.; Park, P-W.; Park, J-Y. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur. J. Clin. Pharmacol., 2009, 65, 609-614.
58. Lin, Y.; Tsai, P.; Lee, M. Impact of flavonoids on matrix metalloproteinase secretion and invadopodia formation in highly invasive A431-III cancer cells materials and methods materials preparation of cell lysates transfection of small interference RNA. PLoS One, 2013, 21, 1-12.
59. Lee, D. E.; Chung, M. Y.; Lim, T. G.; Huh, W. B.; Lee, H. J.; Lee, K. W. Quercetin suppresses intracellular ROS formation, MMP activation, and cell motility in human fibrosarcoma cells. J. Food Sci., 2013, 78, H1464-H1469.
60. Zhang, X-M.; Huang, S-P.; Xu, Q. Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway. Cancer Chemother. Pharmacol., 2004, 53, 82-88.
61. Vijayababu, M. R.; Arunkumar, A.; Kanagaraj, P.; Venkataraman, P.; Krishnamoorthy, G.; Arunakaran, J. Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol. Cell. Biochem., 2006, 287, 109-116.
62. Phromnoi, K.; Yodkeeree, S.; Anuchapreeda, S.; Limtrakul, P. Inhibition of MMP-3 activity and invasion of the MDAMB- 231 human invasive breast carcinoma cell line by bioflavonoids. Acta Pharmacol. Sin., 2009, 30, 1169-1176.
63. Camargo, C. A.; da Silva, M. E. F.; da Silva, R. A.; Justo, G. Z.; Gomes-Marcondes, M. C. C.; Aoyama, H. Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker 256 tumor-bearing rats. Biochem. Biophys. Res. Commun., 2011, 406, 638-642.
64. Lai, W. W.; Hsu, S. C.; Chueh, F. S.; Chen, Y. Y.; Yang, J. S.; Lin, J. P.; Lien, J. C.; Tsai, C. H.; Chung, J. G. Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-κB and matrix metalloproteinase- 2/-9 signaling pathways. Anticancer Res., 2013, 33, 1941-1950.
65. Cao, H. H.; Tse, A. K. W.; Kwan, H. Y.; Yu, H.; Cheng, C. Y.; Su, T.; Fong, W. F.; Yu, Z. L. Quercetin exerts antimelanoma activities and inhibits STAT3 signaling. Biochem. Pharmacol., 2014, 87, 424-434.
66. Pratheeshkumar, P.; Budhraja, A.; Son, Y. O.; Wang, X.; Zhang, Z.; Ding, S.; Wang, L.; Hitron, A.; Lee, J. C.; Xu, M.; Chen, G.; Luo, J.; Sin, X. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One, 2012, 7, e47516.
67. Anand, K.; Asthana, P.; Kumar, A.; Ambasta, R. K. Quercetin mediated reduction of angiogenic markers and chaperones in DLA-induced solid tumours. Asian Pac. J. Cancer Prev., 2011, 12, 2829-2835.
68. Kong, L.; Wu, K.; Lin, H. Inhibitory effects of quercetin on angiogenesis of experimental mammary carcinoma. Chin. J. Clin. Oncol., 2005, 2, 631-636.
69. Long, Q.; Xiel, Y.; Huang, Y.; Wu, Q.; Zhang, H.; Xiong, S.; Liu, Y.; Chen, L.; Wey, Y.; Zhao, X.; Gong, C. Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers. J. Biomed. Nanotechnol., 2013, 9, 965-975.
70. Zhao, D.; Qin, C.; Fan, X.; Li, Y.; Gu, B. Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells. Eur. J. Pharmacol., 2014, 723, 360-367.
71. Furuta, H. E.; Okuda, A.; Kobayashi, K. W. Metabolic genes in cancer: Their roles in tumor progression and clinical implications. Biochim. Biophys. Acta, 2010, 1805, 141- 152.
72. Hanahan, D.; Weinberg, R. A.; Francisco, S. The hallmarks of cancer review university of california at san francisco. Cell, 2000, 100, 57-70.
73. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: The next generation. Cell, 2011, 144, 646-674.
74. Chou, T. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev., 2007, 58, 621-681.
75. Wang, G.; Zhang, J.; Liu, L.; Sharma, S.; Dong, Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One, 2012, 7, e51764.
76. Du, G.; Lin, H.; Wang, M.; Zhang, S.; Wu, X.; Lu, L.; Ji, L.; yu, L. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells. Cancer Chemother. Pharmacol., 2010, 65, 277-287.
77. Temesgen, S.; Fadlalla, K.; Mosley, L.; Katkoori, V.; Turner, T.; Manne, U. Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anti- Cancer Res., 2012, 32, 61-71.
78. Xavier, C. P. R.; Lima, C. F.; Rohde, M.; Pereira-Wilson, C. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother. Pharmacol., 2011, 68, 1449-1457.
79. Chuang-Xin, L.; Wen-Yu, W.; Yao, C.; Xiao-Yan, L.; Yun, Z. Quercetin enhances the effects of 5-fluorouracilmediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-κB. Oncol. Lett., 2012, 4, 775-778.
80. Daker, M.; Ahmad, M.; Khoo, A. S. Quercetin-induced inhibition and synergistic activity with cisplatin - A chemotherapeutic strategy for nasopharyngeal carcinoma cells. Cancer Cell. Int., 2012, 12, 34-41.
81. Zhao, J.; Zhao, J.; Jiao, H. Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells. Appl. Biochem. Biotechnol., 2014, 172, 784-791.
82. Kuhar, M.; Sen, S.; Singh, N. Role of mitochondria in quercetin- enhanced chemotherapeutic response in human nonsmall cell lung carcinoma H-520 cells. Anticancer, 2006, 26, 1297-1304.
83. Nessa, M. U.; Beale, P.; Chan, C.; Yu, J. Q.; Huq, F. Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res., 2011, 3798, 3789-3797.
84. Thangasamy, T.; Sittadjody, S.; Mitchell, G. C.; Mendonza, E. E.; Radhakrishnan, V. M.; Limesand, K. H.; Brud, R. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer, 2010, 10, 1-10.
85. Borska, S.; Sopel, M.; Chmielewska, M.; Zabel, M.; Dziegiel, P. Quercetin as a potential modulator of Pglycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules, 2010, 15, 857-870.
86. Sliutzl, G.; Karlseder, J.; Tempfer, C.; Orel, L.; Holzer, G.; Simon, M. M. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp7O overexpression in. vitro: implication of quercetin as sensitiser in chemotherapy. Br. J. Cancer, 1996, 74, 172-177.
87. Li, J.; Zhu, F.; Lubet, R. A.; De Luca, A.; Grubbs, C.; Ericson, M. E.; D'Alessio, A.; Normanno, N.; Dong, Z.; Bode, A. M. Quercetin-3-methyl ether inhibits lapatinib-sensitive and - resistant breast cancer cell growth by inducing G2/arrest and apoptosis. Mol. Carcinog., 2014, 52, 134-143.
88. Jakubowicz-Gil, J.; Langner, E.; Badziul, D.; Wertel, I.; Rzeski, W. Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. Neurotox. Res., 2014, 26, 64-77.
89. Kavithaa, K.; Sumathi, S.; Paulpandi, M.; Padma, P. R. Increased anticancer efficacy by the combined administration of quercetin in multidrug resistant breast cancer cells. BMR Cancer Res., 2014, 1, 1-13.
90. Chan, S-T.; Yang, N-C.; Huang, C-S.; Liao, J-W.; Yeh, SL. Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in. vitro and in vivo. PLoS One, 2013, 8, e54255.
91. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
92. Casalta-lopes, J.; Abrantes, A. M.; Laranjo, M.; Rio, J.; Gonçalves, A. C.; Oliveiros, B.; Sarmento-Ribeiro, A. B.; Botelho, M. F. Efflux pumps modulation in colorectal adenocarcinoma cell lines: The role of nuclear medicine. J. Cancer Ther., 2011, 2, 408-417.
93. Bussa, S.; Rumi, C.; Cianfriglia, M.; Mancuso, S. Quercetin potentiates the effect of Adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol., 1994, 34, 459-464.
94. Sang, D.; Li, R.; Lan, Q. Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27. Acta. Pharmacol. Sin., 2014, 35, 832-838.
95. Azevedo, M. I.; Pereira, A. F.; Nogueira, R. B.; Rolim, F. E.; Brito, G. A.; Wong, D. V.; Lima-Júnior, R. C.; Ribeiro, R. A. R.; Vale, M. L. The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatininduced chronic painful peripheral neuropathy. Mol. Pain, 2013, 9, 53.
96. Chen, J.; Hu, R.; Chou, H. Quercetin-induced cardioprotection against doxorubicin cytoxicity. J. Biomed. Sci., 2013, 20, 2-10.
97. Dong, Q.; Chen, L.; Lu, Q.; Sharma, S.; Li, L.; Morimoto, S.; Wang, G. Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression. Br. J. Pharmacol., 2014, 171, 4440-4454.
98. Priego, S.; Feddi, F.; Ferrer, P.; Mena, S.; Benlloch, M.; Ortega, A.; Carretero, J.; Obrador, E.; Asensi, M.; Estrela, J. M. Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: A Bcl- 2- And superoxide dismutase 2-dependent mechanism. Mol. Cancer Ther., 2008, 7, 3330-3342.
99. Pozsgai, E.; Bellyei, S.; Cseh, A.; Boronkai, A.; Racz, B.; Szabo, A.; Sumegi, B.; Hocsak, E. Quercetin increases theefficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway. Nutr. Cancer, 2013, 65, 1059-66.
100. Varadkar, P.; Dubey, P.; Krishna, M.; Verma, N. C. Modulation of radiation-induced protein kinase C activity by phenolics. J. Radiol. Prot., 2001, 21, 361-370.
101. Lin, C.; Yu, Y.; Zhao, H. G.; Yang, A.; Yan, H.; Cui, Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother. Oncol., 2012, 104, 395-400.
102. van Rijn, J.; van den Berg, J. Flavonoids as enhancers of xray- induced cell damage in hepatoma cells. Clin. Cancer Res., 1997, 3, 1775-1779.
103. Horton, J. A.; Li, F.; Chung, E. J.; Hudak, K.; White, A.; Krausz, K.; Gonzalez, F.; Citrin, D. Quercetin inhibits radiation- induced skin fibrosis. Radiat. Res., 2013, 180, 205-215.
104. Das, D. K. R.; Chakraborty, A.; Sinha, M.; Manna, K.; Mukherjee, D.; Chakraborty, A.; Bhattacharjee, S.; Dey, S. Modulatory role of quercetin against gamma radiationmediated biochemical and morphological alterations of red blood cells. Int. J. Radiat. Biol., 2013, 89, 471-481.
105. Orsolic, N.; Benkovic, V.; Horvat-Knezevic, A.; Kopjar, N.; Kosalec, I.; Bakmaz, M.; Mihaljevic, Z.; Bendelja, K.; Basic, I. Assessment by survival analysis of the radioprotective properties of propolis and its polyphenolic compounds. Biol. Pharm. Bull., 2007, 30, 946-951.